KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ DI CĂN NÃO CÓ ĐỘT BIẾN EGFR BẰNG THUỐC ỨC CHẾ TYROSIN KINASE THẾ HỆ 1 VÀ 2

Abstract

Objectives: To describe some clinical and paraclinical features of brain metastatic non-small cell lung cancer with EGFR mutations by 1st and 2nd generation tyrosin kinase inhibitors. Evaluation of the treatment results of the study group of patients. Subjects and methods: a retrospective descriptive study on 89 patients with brain metastatic non-small cell lung cancer with EGFR mutations who received first-line treatment with 1st and 2nd generation TKIs at K hospital since 04/2019 to 04/2023. Results: In the study, the number of patients receiving first-line treatment with erlotinib, gefitinib and afatinib were 33, 34, 22, respectively. The average age of participating in the study was 59.6 ± 9.50 years old, of which male accounted for 48,3%, female accounted for 51,7%. All patients had common gene mutations in which, 60.7% of patients had Del19 mutation and 39.3% had L858R mutation. 53.9% of patients in the study were treated in combination with brain tumor radiosurgery, 20.2% were treated with whole brain radiation. The disease control rate was 94,4%, the median mPFS progression-free survival was 12,6 months; progression-free survival at 12 months was 54,7%. The intracranial response rate was 96,6%, the median cerebral mPFS was 14,7 months. Common side effects in clinical and subclinical are rash common in 49,4%, diarrhea in 22,5%, interstitial inflammation in 19,1%, increase in liver enzymes in 37,1%, decrease in hemoglobin in common in 30,3% of treated patients, mainly grade 1, 2. Conclusion: TKIs treatment step 1 in the group of subjects with brain metastatic NSCLC with EGFR mutation achieved a high response rate, improved PFS, and tolerable mild toxicity.